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Abstract
Background: We have previously reported that electroacupuncture (EA) pretreatment induced tolerance against
cerebral ischemic injury, but the mechanisms underlying this effect of EA are unknown. In this study, we assessed
the effect of EA pretreatment on the expression of a7 nicotinic acetylcholine receptors (a7nAChR), using the
ischemia-reperfusion model of focal cerebral ischemia in rats. Further, we investigated the role of high mobility
group box 1 (HMGB1) in neuroprotection mediated by the a7nAChR and EA.
Methods: Rats were treated with EA at the acupoint “Baihui (GV 20)” 24 h before focal cerebral ischemia which
was induced for 120 min by middle cerebral artery occlusion. Neurobehavioral scores, infarction volumes, neuronal
apoptosis, and HMGB1 levels were evaluated after reperfusion. The a7nAChR agonist PHA-543613 and the
antagonist a-bungarotoxin (a-BGT) were used to investigate the role of the a7nAChR in mediating
neuroprotective effects. The roles of the a7nAChR and HMGB1 release in neuroprotection were further tested in
neuronal cultures exposed to oxygen and glucose deprivation (OGD).
Results: Our results showed that the expression of a7nAChR was significantly decreased after reperfusion. EA
pretreatment prevented the reduction in neuronal expression of a7nAChR after reperfusion in the ischemic
penumbra. Pretreatment with PHA-543613 afforded neuroprotective effects against ischemic damage. Moreover, EA
pretreatment reduced infarct volume, improved neurological outcome, inhibited neuronal apoptosis and HMGB1
release following reperfusion, and the beneficial effects were attenuated by a-BGT. The HMGB1 levels in plasma
and the penumbral brain tissue were correlated with the number of apoptotic neurons in the ischemic penumbra.
Furthermore, OGD in cultured neurons triggered HMGB1 release into the culture medium, and this effect was
efficiently suppressed by PHA-543,613. Pretreatment with a-BGT reversed the inhibitory effect of PHA-543,613 on
HMGB1 release.
Conclusion: These data demonstrate that EA pretreatment strongly protects the brain against transient cerebral
ischemic injury, and inhibits HMGB1 release through a7nAChR activation in rats. These findings suggest the novel
potential for stroke interventions harnessing the anti-inflammatory effects of a7nAChR activation, through
acupuncture or pharmacological strategies.
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One of the top killers of human, stroke claims hundreds
of thousands of lives every year throughout the world.
To fulfill the increasing need for effective and practical
intervention strategies, it is important to gain a better
understanding of neuroprotective mechanisms in the
brain [1]. Preconditioning, as a potent endogenous pro-
tective maneuver, activates several endogenous signaling
pathways that result in tolerance against ischemia. Iden-
tification of these pathways and their targets will likely
contribute to the development of novel therapeutic con-
cepts [2]. We previously reported that electroacupunc-
ture (EA) pretreatment afforded strong protection
against transient cerebral ischemic injury [3,4]. However,
the signaling mechanisms mediating the effects of EA
pretreatment are unclear.
Acute ischemic stroke involves a complex array of pro-
cesses involving multiple biological systems, the com-
bined action of which determines the outcome of the
ischemic event [5]. Among these processes, a growing
body of data implicates an integral role for inflammation,
which forms an important component of the interactions
between the nervous and immune systems in stroke
pathology [6,7]. Endogenous anti-inflammatory mechan-
isms function to control the inflammatory response and
prevent injury induced by an excessive immune response.
The cholinergic anti-inflammatory pathway represents a
physiological mechanism by which the nervous system
interacts with the innate immune system to restrain sys-
temic inflammatory responses [8]. There is convincing
evidence of the critical importance of the a7 nicotinic
acetylcholine receptor (a7nAChR) in mediating choliner-
gic anti-inflammatory signaling [9].
It is known that a7nAChR-dependent cholinergic sig-
naling is implicated in suppressing the release of high
mobility group box 1 (HMGB1) [10]. HMGB1 has impor-
tant functions in mediating the pathology of acute damage
and subsequent inflammatory processes in the post-
ischemic brain [11-13]. Experimental and clinical studies
have demonstrated that the anti-inflammatory actions of
acupuncture are mediated via central inhibition of the
innate immune system as a result of vagal activity [14].
Moreover, recent studies using animal models of Parkin-
son’s disease and amyotrophic lateral sclerosis have shown
that neuroprotection by acupuncture or EA may be
mediated via inhibition of the neuroinflammatory response
[15,16].
We hypothesized that EA may exert neuroprotective
effects in stroke by regulating the expression of
a7nAChR, and tested this using the middle cerebral
artery occlusion (MCAO) model of focal ischemia in rats.
We also investigated the possible role of HMGB1 sup-
pression in mediating this effect, both in rats subjected to
ischemia and in neuronal cultures subjected to oxygen-
and glucose deprivation (OGD).
Materials and methods
Animal Care and Drugs
The experimental protocol used in this study was
approved by the Ethics Committee for Animal Experi-
mentation of the Fourth Military Medical University and
was conducted according to the Guidelines for Animal
Experimentation of the Fourth Military Medical Univer-
sity (Xi’an, China). Male Sprague-Dawley rats, weighing
280-320 g, were provided by the Experimental Animal
Center of the Fourth Military Medical University, and
housed under controlled conditions with 12-hour light/
dark cycle, temperature of 21 ± 2°C, and 60-70% humid-
ity, for at least one week prior to drug treatment or sur-
gery. The rats were allowed for free access to standard
rodent diet and tap water.
The specific a7nAChR antagonist a-bungarotoxin (a-
BGT) was obtained from Alexis Biochemicals Corpora-
tion (San Diego, CA, USA), and was made up in 150
mM NaCl before use. Because a-BGT does not pene-
trate the blood-brain barrier, the drug was administered
intracerebroventricularly at a dose of 0.5 μg/kg accord-
ing to a previous study [17].
The N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]
pyridine-5-carboxamide hydrochloride (PHA-543,613
hydrochloride) is a potent and selective agonist for the
a7 subtype of neuronal nicotinic acetylcholine receptors,
with a high level of brain penetration and good oral
bioavailability [18]. PHA-543,613 hydrochloride was pur-
chased from Tocris Bioscience (Ellisville, MO, USA),
and was dissolved in saline before intraperitoneal injec-
tion (1.0 mg/kg) [18].
Dimethylsulfoxide (DMSO) and 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltera-zolium bromide (MTT) were pur-
chased from Sigma-Aldrich Co. (St. Louis, MO, USA).
The lactate dehydrogenase (LDH) kit was provided by the
Jiancheng Bioengineering Institute (Nanjing, China).
Experimental protocols
The numbers of animals per group for various experi-
ments at different time points are summarized in
Table 1.
To determine the effect of EA pretreatment on
a7nAChR expression after ischemia-reperfusion, rats
were randomly assigned to one of three groups: Sham,
MCAO, or EA+MCAO (n = 8 rats/group). The rats in
the Sham group underwent identical surgery without
MCAO. The animals in the EA+MCAO group received
daily EA preconditioning for consecutive 5 days, and
were subjected to MCAO 24 h after the end of the last
EA pretreatment. The expression of a7nAChR was
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escent staining.
To evaluate the neuroprotective effect of pretreatment
with PHA-543,613, rats were treated with 1 mg/kg PHA-
543,613 or 1 mL vehicle (saline) once daily for 5 days, and
were subjected to MCAO at 24 h after the end of the last
PHA-543,613 pretreatment. The neurological scores and
infarct volumes were evaluated at 72 h after reperfusion.
To assess the effect of a-BGT on EA-induced neuropro-
tection and HMGB1 release following cerebral ischemia-
reperfusion, rats were randomly assigned to Sham,
MCAO, EA+MCAO, a-BGT+MCAO, a-BGT+EA and
vehicle+EA groups (n = 20 rats/group). The rats in the
Sham, MCAO and EA+MCAO groups received the treat-
ments described above. Rats in the a-BGT+MCAO group
received intracerebroventricular a-BGT (0.5 μg/kg) once a
day for 5 days and were subjected to MCAO at 24 h after
the last injection. Rats in the vehicle+EA group and the
a-BGT+EA group received saline (10 μL) and a-BGT
(0.5 μg/kg), respectively, at 30 min before the onset of EA,
once a day for 5 days, and were subjected to MCAO at
24 h after the end of the last EA pretreatment. The neuro-
logical scores, infarct volumes, neuronal apoptosis and
HMGB1 levels in the penumbral brain tissue and plasma
were evaluated at 72 h after reperfusion.
All animals were anesthetized with sodium pentobar-
bital (40 mg/kg, i.p.) while undergoing EA stimulation
or surgery. During anesthesia, rats inhaled oxygen via a
face mask at a flow rate of 1 L/min to avoid potential
hypoxia associated with anesthesia.
To further investigate the involvement of inhibition of
HMGB1 release through a7nAChR activation, neuronal
cultures were exposed to OGD to simulate cerebral
ischemia and the HMGB1 concentration in the culture
medium was tested in the presence and absence of
PHA-543,613.
Intracerebral Ventricular Injection
The rats were anesthetized and placed in a stereotaxic
apparatus (Narishige, Tokyo, Japan). A scalp incision
was made and bregma was exposed. A burr hole was
drilled in the bone 1.5 mm lateral and 1.0 mm posterior
to bregma at the right hemisphere. A stainless steel 26-
gauge cannula (Plastics One Inc., C315G) was slowly
introduced through the burr hole into the right lateral
ventricle (3.8 mm beneath the dural surface). The can-
nula was fixed by dental cement and four stainless steel
screws secured to the skull and occluded. The rats were
allowed to recover from surgery for at least 3 days
before experiments began. Vehicle or a-BGT was
infused into the right lateral ventricle using a 25 μL
Hamilton syringe (80630, Hamilton Co., Reno, NV,
USA) at a rate of 0.5 μL/min and the needle was left for
an additional 5 min before withdrawal to prevent reflux.
The 25 μL Hamilton syringe was connected to the can-
nula by a PE-50 catheter.
Electroacupuncture Pretreatment
EA pretreatment was performed as previously described
[3,4] at the acupoint “Baihui (GV 20)”, which is located at
the intersection of the sagittal midline and the line link-
ing the two ears. Briefly, animals were anesthetized, and
the acupoint “Baihui (GV 20)” was stimulated at an
intensity of 1 mA and a frequency of 2/15 Hz for 30 min,
using the Hwato Electronic Acupuncture Treatment
Instrument (Model No. SDZ-V, Suzhou Medical Appli-
ances Co., Ltd., Suzhou, China). The core temperature of
all the rats was maintained at 37.0 ± 0.5°C during EA pre-
treatment by surface heating or cooling (Spacelabs Medi-
cal Inc., Redmond, WA). The right femoral artery was
cannulated for continuous monitoring of blood pressure
and for arterial blood sampling. Arterial blood gases and
plasma glucose were measured at the onset of EA, 15
min after EA and at the end of EA. pO2,p C O 2,a n dp H
were quantified using a blood gas analyzer (ABL700,
Radiometer, Denmark), and plasma glucose was mea-
sured with a blood glucose meter (OneTouch UltraEasy,
Johnson & Johnson, USA).
Transient Focal Cerebral Ischemia
Focal cerebral ischemia was induced by MCAO using an
intraluminal filament technique as described in our
Table 1 Numbers of animals per group for various experiments at different time points
Protocol Experiment Time point Group Number Total
Effect of EA pretreatment on a7nAChR
expression
Western blot analysis
Immunofluorescent staining
24 h, 48 h,
72 h 72 h
Sham, Control, EA n = 5
n=3
44
Neuroprotective effect of PHA-543,613
pretreatment
Neurological evaluation and
TTC staining
72 h MCAO, PHA-543,613+MCAO, Vehicle
+MCAO
n = 10 30
Effect of a-BGT on EA pretreatment induced
neuroprotection and HMGB1 release
Neurological evaluation and
TTC staining
72 h Sham, MCAO, EA+MCAO, a-BGT+EA,
Vehicle+EA, a-BGT+MCAO
n = 10 120
TUNEL staining 24 h n = 5
ELISA for HMGB1 level 72 h n = 5
EA, electroacupuncture; HMGB1, high mobility group box 1; MCAO, middle cerebral artery occlusion; TTC, 2,3,5-triphenyltetrazolium chloride; TUNEL, terminal
deoxynucleotidyl transferase-mediated dUDP-biotin nick end-labeling; a7nAChR, a7 nicotinic acetylcholine receptor; a-BGT, a-bungarotoxin.
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frame, and a scalpel was used to make an incision on
the scalp and carefully scrape the exposed skull. The
skull (4 mm lateral and 2 mm caudal to bregma) was
thinned without perforation by a drill. Regional cerebral
blood flow (rCBF) was monitored through a disposable
microtip fiber optic probe (diameter 0.5 mm), which
was attached to the skull with a probe holder, and con-
nected through a Master Probe to a laser Doppler com-
puterized main unit (PeriFlux 5000, Perimed AB,
Sweden). The MCAO was considered adequate if the
rCBF showed a sharp drop to 20% and recovered up to
more than 80% of baseline (pre-ischemia) level; animals
that did not meet this requirement were excluded.
Neurobehavioral Evaluation and Infarct Assessment
At 72 h after reperfusion, the animals were neurologi-
cally assessed by an investigator who was unaware to
animal grouping. An 18-point scoring system reported
by Garcia et al.[20] with modifications was used for
neurologic assessment.
The infarct volume was assessed by 2,3,5-triphenylte-
trazolium chloride (TTC, Sigma-Aldrich, St. Louis, MO)
staining as previously described [4,19]. At 72 h after
reperfusion, the rats were re-anesthetized with 4% iso-
f l u r a n ei no x y g e na n dd e c a p i t a t e d .T h eb r a i n sw e r e
rapidly removed and were sliced into 2-mm thick coronal
sections with the aid of a brain matrix. Sections were
stained with standard 2% TTC, for 10 minutes at 37°C,
followed by overnight immersion in 4% paraformalde-
hyde, and were photographed with a digital camera
(Kodak DC240, Eastman Kodak Co., Rochester) con-
nected to a computer. Unstained areas were defined as
infarct, and were measured using Adobe Photoshop 8.0
CS for Windows by an investigator blinded to the experi-
mental grouping. To account for cerebral edema and dif-
ferential shrinkage resulting from tissue processing, the
total volume of the infarction was presented as a percen-
tage of the contralateral hemisphere.
TUNEL Staining
Samples from 5 groups (MCAO, EA+MCAO, a-BGT
+EA, vehicle+EA, a-BGT+MCAO, n = 5 per group) in
a7nAChR-blocking experiments were used for TUNEL
staining. Twenty-four hours after reperfusion, neuronal
apoptosis in the ischemic penumbra was assessed in situ
by TUNEL staining as described in our previous study
[4]. The TUNEL staining was quantitatively evaluated
using the method described by Wang et al. [21]. Briefly,
32 pixels of 0.10 mm
2 were located under a light micro-
scope with 100 × magnification, and the total number of
positively stained cells in these pixels was counted and
expressed as cells/mm
2.
Western Blot Analysis of a7nAChR
At 24 h, 48 h, and 72 h after reperfusion, rats (n = 5 per
time point per group) were deeply anesthetized, and the
ischemic penumbras were microdissected according to
established protocols in rodent models of unilateral proxi-
mal MCAO [22,23]. Briefly, a 4-mm thick coronal brain
slice was cut, beginning 6 mm from the anterior tip of the
frontal lobe. Then a longitudinal cut (from top to bottom)
was made approximately 2 mm from the midline through
the ischemic hemisphere to remove medial parts. Finally, a
transverse diagonal cut was made at approximately the
“2o ’clock” position to separate the wedge-shaped penum-
bra. The tissue was homogenized on ice in RIPA lysis buf-
fer (Beyotime, Nantong, China) with 1 × Roche complete
protease inhibitor cocktail and 1 mM phenylmethylsulfo-
nyl fluoride (PMSF), and western blot was performed as
previously described [10]. The following primary antibo-
dies were used in this study: anti-a7nAChR rabbit polyclo-
nal antibody (Santa Cruz Biotechnology, Cat# sc-5544,
1:200 dilution) and anti-b-actin mouse monoclonal anti-
body (Santa Cruz Biotechnology, Cat# sc-130300, 1:1000
dilution). Appropriate secondary horseradish peroxidase-
conjugated goat anti-rabbit (Cat# 32460) or goat anti-
mouse antibodies (Cat# 32430) (Pierce Biotechnology Inc.,
1:5000 dilution) were used.
Semi-quantitative analysis of the blots was performed
using densitometry followed by quantification with the
NIH image program (NIH Image Version 1.61). Each
sample was subjected to immunoblotting three times,
and the final optical density value (relative to that for
the internal standard) represents the average of these
three separate analyses.
Double Immunofluorescence for a7nAChR and NeuN
At 72 h after reperfusion, the rats (n = 3 for each group)
were deeply anesthetized and transcardially perfused with
PBS and 4% paraformaldehyde as described previously
[4]. To ensure that homologous areas of injury were
sampled between animals, parallel sets of sections from
-3.0 to -5.0 mm from Bregma (covering the infarct area)
were used. The 10-μm thick coronal sections were incu-
bated for 12 h at room temperature with the following
primary antibodies: anti-a7nAChR rabbit polyclonal anti-
body (Santa Cruz Biotechnology, Cat# sc-5544, 1:200
dilution) and anti-NeuN mouse monoclonal antibody
(Chemicon International Inc., Cat# MAB377, 1:1000
dilution). After washing three times with PBS, sections
were incubated for 1 h at room temperature with FITC-
labeled goat-anti mouse IgG (Molecular Probes Inc.,
Cat# 62-6511, 1:800 dilution) and Alexa Fluor 594-
labeled goat-anti rabbit IgG (Invitrogen, Cat# A11012,
1:800 dilution). Sections incubated without primary or
secondary antibodies served as negative controls. Finally,
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an Olympus BX-60 fluorescence microscope (Olympus
Corporation, Japan).
Neuronal cultures and OGD
Neuronal cultures were prepared from 17-19 day
embryos of Sprague-Dawley rats. The cortical neurons
were suspended in neuron-defined culture medium and
plated onto poly-L-lysine-coated 35-mm dishes (3 × 10
5
cells per dish). Neurobasal medium supplemented with
2% B27, 0.3 mM L-glutamine and 1% penicillin-strepto-
mycin was used (Invitrogen Gibco, NY, USA). Half of
the medium was replaced every 3 days. The purity of
the neuronal cultures was confirmed by microtubule
associated proteins-2 (MAP-2) staining showing that the
cultures were > 95% neurons.
After 13 days in vitro, neurons were exposed to OGD
as previously described [24]. In brief, the culture med-
ium was replaced with serum- and glucose-free medium
and placed in an incubator chamber (Billups-Rothen-
burg, CA, USA), which was flushed for 5 min with 95%
nitrogen and 5% CO2 and then sealed at 37°C for 90
min (hypoxia). Control cultures were incubated for the
same period of time at 37°C in a humidified atmosphere
of 95% air and 5% CO2.
The PHA-543,613 (0.1, 0.5, 2.5, and 12.5 μM) was
added to neuronal cultures immediately preceding
OGD. In separate a7nAChR-blocking experiments, we
pre-treated neuronal cultures with a-BGT (10 nM) for
30 min at 37°C prior to OGD in the presence or
absence of PHA-543,613. The concentration of a-BGT
in this experiment was chosen based on previous studies
[25,26], in which 10 nM of a-BGT did not show cyto-
toxicity, but could essentially block a7nAChR-mediated
biological effects.
MTT cell survival assay and Lactate dehydrogenase
release
At 24 h after the exposure of the neuronal monocultures
to OGD, cell viability was assessed by the ability of cells to
take up MTT [24]. In brief, aliquots of MTT solution
(final concentration of 0.2 mg/mL) were added to medium
and the cells were incubated for 4 h at 37°C. After the
medium had been removed, the dye crystals were solubi-
lized by adding 200 μl of DMSO, and the absorption at
570 nm was measured with a Model 550 microplate reader
(Bio-Rad lab, California, USA). The relative cell viability
for each group was expressed as a percentage of the mean
OD570 value of the control group.
Lactate dehydrogenase (LDH) release is an indicator of
plasma membrane damage and is commonly used for
the assessment of necrotic cell death. At 24 h after
OGD, LDH activity in the culture medium was deter-
mined using a commercially available assay (Jiancheng
Bioengineering Institute, Nanjing, China) according to
the manufacturer’s protocol. The activity unit was
defined as units per deciliter.
HMGB1 analysis
At 72 h after reperfusion, blood samples (1 mL, n = 5 per
group) were collected via cardiac puncture immediately
following euthanasia, then centrifuged at 2,000 g for
20 min at 4°C. After centrifugation, the plasma was frozen
at -80°C until further testing. Samples of ischemic penum-
bra were microdissected and weighed. The cytoplasmic
fraction of brain tissue was prepared as previously
reported [27]. In brief, the brain tissues of the ischemic
penumbra were gently homogenized in 10 mM N-2-
hydroxyethylpiperazine-N’-ethanesulfonic acid (HEPES)/
10 mM KCl buffer with 0.08% NP-40, 0.1 mM ethylene-
diaminetetraacetic acid (EDTA), 0.5 mM dithiothreitol
(DTT), and 0.5 mM phenylmethylsulfonyl fluoride
(PMSF), and the soluble fraction derived from the cyto-
plasm was kept at -80°C until further testing.
The HMGB1 levels in the neuronal culture medium,
the brain cytoplasmic fraction, and the plasma were ana-
lyzed with an HMGB1 ELISA Kit II (Shino-test Cor-
poration, Kanagawa, Japan). The cytoplasmic protein
concentration was determined as described by Bradford
[28]. The final results were presented as ng/mg protein
in cytoplasm and as ng/mL in culture medium and
plasma.
Statistical Analysis
Brain sections were examined by two independent and
blinded investigators. SPSS 13.0 for Windows (SPSS Inc.,
Chicago, IL) was used to conduct statistical analyses. All
values, except for neurological scores, were presented as
mean ± SEM, and were analyzed by one-way analysis of
variance. Between-group differences were detected with
Tukey’s post hoc tests. The neurological deficit scores were
expressed as median (interquartile range) and were ana-
lyzed with Kruskal-Wallis test followed by the Mann-
Whitney U test with Bonferroni correction. The correla-
tion between the numbers of apoptotic neuronal cells in
the ischemic penumbra and HMGB1 levels was analyzed
statistically using Pearson’s correlation coefficient. A P
value of less than 0.05 was considered to be statistically
significant.
Results
Physiological Parameters
There were no significant differences in physiological
parameters during EA pretreatment (at the onset of EA,
15 min after EA and the end of EA) or surgery (at the
onset of ischemia, 60 min after the onset of ischemia,
and 30 min after reperfusion). Arterial blood gases (pO2,
pCO2, pH), mean arterial pressure, body temperature
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ing the experimental period. Regional cerebral blood
flow (rCBF) was monitored in the period of transient
focal cerebral ischemia and reperfusion in order to meet
the ischemic requirement (data not shown).
Expression of a7nAChR following ischemia-reperfusion
The expression of a7nAChR was significantly decreased
in the MCAO group compared to Sham animals (P <
0.01). EA pretreatment produced an evident inhibition of
t h i sr e d u c t i o na t2 4h ,4 8ha n d7 2ha f t e rr e p e r f u s i o n( P
< 0.05). There was no difference in a7nAChR expression
between different time points within groups (Figure 1).
Neuronal expression of a7nAChR in ischemic penumbra
As shown in Figure 2, a7nAChR expression was observed
throughout the hemisphere in the Sham group, whereas it
was significantly decreased in the ischemic penumbra in
the MCAO group. EA pretreatment inhibited this reduc-
tion at 24 h, 48 h and 72 h after reperfusion. Double
immunofluorescence for a7nAChR and NeuN showed
that a7nAChR was mainly localized in neurons.
PHA 543613 Pretreatment Induces Neuroprotection
Pretreatment with the a7nAChR agonist PHA-543,613
significantly improved the neurological scores and reduced
the infarction volumes measured at 72 h after reperfusion
compared with the MCAO group (P < 0.05). There was
no statistically significant difference between the MCAO
group and the vehicle+MCAO group (Figure 3).
Effect of a-BGT on neuroprotection induced by EA
pretreatment
The effects of a-BGT on neuroprotection induced by
EA pretreatment are summarized in Figure 4. At 72 h
after reperfusion, the EA+MCAO group showed smaller
brain infarct volumes compared with the MCAO group
(P < 0.01). In the a-BGT+EA group, the infarct volume
was similar to that in the MCAO group, and larger than
that in the EA+MCAO group (P < 0.01). The average
infarct volume in the vehicle+EA group was significantly
different from that in the MCAO group (P < 0.01), and
was similar to that in the EA+MCAO group. The infarct
volume in the a-BGT+MCAO group was not signifi-
c a n t l yd i f f e r e n tf r o mt h a ti nt h eM C A Og r o u p( F i g u r e
4B). A similar blocking effect of a-BGT on the effect of
EA was observed for the neurological scores (Figure 4C).
Effect of a-BGT on neuronal apoptosis in ischemic
penumbra
As shown in Figure 5, little positive TUNEL staining
(brown) was detected in brain sections of sham animals
at 72 h after reperfusion, whereas large numbers of
TUNEL-positive cells were seen in the ischemic penum-
bra in the MCAO, a-BGT+EA and a-BGT+MCAO
groups. In contrast, only a small amount of TUNEL
staining was observed in the EA+MCAO and vehicle
+EA groups. Quantitative analysis showed that the EA
pretreatment significantly reduced the number of
TUNEL-positive cells, compared to the MCAO, a-BGT
+EA and a-BGT+MCAO groups. There was no differ-
ence between the MCAO, a-BGT+EA and a-BGT
+MCAO groups.
HMGB1 levels in the penumbral brain tissue and plasma
Figure 6 shows the levels of HMGB1 in the penumbral
brain tissue and plasma at 72 h after reperfusion. The
HMGB1 content in the penumbra was significantly
i n c r e a s e di nt h eM C A Og r o u pc o m p a r e dt ot h a ti nt h e
Sham group (P < 0.01). The HMGB1 content was signif-
icantly lower in the EA+MCAO and vehicle+EA groups
compared to that in the MCAO group (P < 0.01). There
was no difference between the MCAO, a-BGT+EA and
a-BGT+MCAO groups (Figure 6A). Similar changes
were observed for plasma HMGB1 levels (Figure 6B).
We found significant positive correlations between the
numbers of apoptotic neurons and the brain HMGB1
content (r = 0.8409, P < 0.01; Figure 6C) and the num-
ber of apoptotic neurons and the plasma HMGB1 con-
centration (r = 0.7263, P < 0.01; Figure 6D).
Figure 1 Temporal expression of a7nAChR protein in the
ischemic penumbra. (A) Western blot showing representative
a7nAChR protein expression at 24 h, 48 h, and 72 h after
reperfusion, in the ischemic penumbra and in the sham-operated
group. (B) The density of a7nAChR protein expression relative to b-
actin protein expression. Data are means ± SEM (n = 5 per time
point per group). *P < 0.01 vs. Sham, #P < 0.05 vs. Con.
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in primary neurons
To ensure that HMGB1 release was not caused by non-
specific protein release due to cell damage, the toxicity of
PHA-543,613 (0.1-12.5 μM) and a-BGT (10 nM) was
tested under conditions of normoxia using the MTT assay.
The drugs did not have any influence on cell viability at
these concentrations after incubation for 24 h (Figure 7A).
The viability of neurons was assessed at 24 h after a
90-min exposure to OGD. PHA-543,613 increased the
viability of neurons exposed to OGD in a concentration-
dependent manner (Figure 7B) and attenuated LDH
release resulting from OGD (Figure 7C). However, pre-
treatment with a-BGT completely abolished the protec-
tive effect of PHA-543,613. Exposure of neurons to
OGD for 90 min triggered HMGB1 release into the cul-
ture medium, and this was efficiently suppressed by
PHA-543,613 in a concentration-dependent manner.
Pretreatment with a-BGT reversed the inhibitory effect
of PHA-543,613 on HMGB1 release (Figure 7D).
Figure 2 Immunofluorescent double-labeling of a7nAChR and NeuN. Representative double immunofluorescence staining for NeuN (neuronal
marker, green) and a7nAChR (red) in the ischemic penumbra (n = 3). The a7nAChR was colocalized with neurons at 72 h after reperfusion. EA
pretreatment suppressed the down-regulation of neuronal a7nAChR in the ischemic penumbra following reperfusion. Scale bars = 50 μm.
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Focal cerebral ischemia evokes a robust inflammatory
response that begins within a few hours of onset and
typifies the secondary or delayed response to ischemia.
Activation of the innate immune response is a conse-
quence of stroke, and preclinical data indicate that
inflammation in the immediate post-stroke period con-
tributes to ischemic brain injury [29]. Nervous system
interaction with the immune system is vital for modulat-
ing innate immune responses and controlling inflamma-
tion [6]. The cholinergic anti-inflammatory pathway is a
neural a7AChR-dependent mechanism that suppresses
the innate inflammatory response [9,30], and provides
novel opportunity for improving stroke therapy. The
neuroprotective effects of a7AChR in the pathophysiol-
ogy of cerebral ischemia-reperfusion have recently been
reported by several investigators [31,32]. However, the
expression and role of a7AChR in neuroprotection by
EA pretreatment is still unclear.
In the present study, we found that a7AChR protein
expression began to decrease in the ischemic penumbra
at 24 h and remained low for at least 72 h following
reperfusion. EA pretreatment reversed this reduction in
a7AChR expression. In addition, our immunofluores-
cent staining showed that the a7AChR immunoreactiv-
ities were colocalized with NeuN immunoreactivities,
indicating that the effect of EA pretreatment on
a7nAChR expression was neuron-specific. These results
Figure 3 Neuroprotection by pretreatment with PHA-543,613. (A) Representative photographs of coronal brain sections following infarction,
stained with 2,3,5-triphenyltetrazolium chloride. Red area is healthy tissue; white area is infarct tissue. Pretreatment with PHA-543,613 significantly
reduced the infarction volumes (B) and improved the neurological scores (C) compared with the MCAO group. (n = 10) *P < 0.05 vs. MCAO and
vehicle groups.
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gulation plays a role in producing neuronal damage in
ischemia, and that EA may be neuroprotective by pre-
venting this mechanism.
Activation of a7AChR with PHA-543,613 pretreatment
significantly improved the neurological scores and
reduced the infarction volumes. Moreover, the a7AChR
antagonist a-BGT attenuated the beneficial effects of EA
on infarct volumes, neurological outcomes, and apopto-
sis. Given alone, a-BGT had no significant effect on neu-
rological outcomes, infarct volume, or neuronal
apoptosis, indicating that a7AChRs blockade did not
have any direct aggravating effect in these experiments.
These results suggest that activation of the a7nAChR
may be an essential mediator of the EA effect, acting to
switch the cells from a vulnerable to a tolerant state.
There is a wealth of evidence to support that the sys-
temic inflammatory response associated with ischemia-
reperfusion injury contributes to the morbidity and mor-
tality associated with stroke [7,29]. HMGB1, originally
identified as a nuclear DNA-binding protein, has recently
been characterized as a cytokine-like mediator of systemic
inflammation [10]. In the pathophysiology of cerebral
ischemia-reperfusion, HMGB1 is released from neurons
early following ischemic injury, and acts as a mediator
linking acute brain damage and subsequent inflammatory
processes [11-13]. Our finding of increased HMGB1 levels
in the brain cytoplasm and plasma suggest that exacer-
bated HMGB1 release may be triggered by ischemia/reper-
fusion and play a role in enhancing the inflammatory
response. The elevation of plasma HMGB1 may be asso-
ciated with the passive release of HMGB1 from the
damaged brain. Consistent with this, serum HMGB1 levels
were significantly elevated in patients with cerebral ische-
mia [33], suggesting the potential role of this protein as a
therapeutic target. Intravenous injection of neutralizing
anti-HMGB1 monoclonal antibody has been suggested as
a novel therapeutic strategy for ischemic stroke [34]. We
found that EA pretreatment counteracted the increase in
HMGB1 levels in brain and plasma after reperfusion, and
these beneficial effects were attenuated by a7nAChR
blockade. Thus, EA pretreatment may suppress HMGB1
after ischemia-reperfusion via the activation of a7nAChR.
The findings that a7nAChR activation protected against
OGD-induced cellular damage in cultured neurons, and
that this action was blocked by an a7nAChR antagonist,
confirms the neuroprotective role of this receptor. The
increased HMGB1 released into the culture medium seen
after OGD is consistent with our in vivo data, and the sup-
pression of HMGB1 release by the a7nAChR agonist
argues for an important role of the cholinergic system in
protecting against this effect. This was further supported
Figure 4 Neurological scores and infarct sizes at 72 h after reperfusion. (A) Representative photographs of coronal brain sections following
infarction, stained with 2,3,5-triphenyltetrazolium chloride. Red area is healthy tissue; white area is infarct tissue. Pretreatment with EA
significantly reduced infarct sizes (B) and improved neurological scores (C) and the a7nAChR antagonist a-BGT reversed the beneficial effect of
EA pretreatment (n = 10). *P < 0.01 vs. MCAO, #P < 0.01 vs. EA+MCAO.
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by pretreatment with the a7nAChR antagonist a-BGT.
Taken together, these findings are consistent with a pro-
tective effect of a7nAChR-mediated inhibition of HMGB1
release after cerebral ischemia, and indicate that EA pre-
treatment can activate this protective pathway.
There is compelling evidence that neurons in the
ischemic penumbra may undergo apoptosis after several
Figure 5 Neuronal apoptosis at 72 h after reperfusion.( Upper) Representative photomicrographs of TUNEL staining in the ischemic
penumbra. The arrowhead indicates TUNEL-positive cell. Scale bars = 20 μm. (Bottom) Quantitative analysis of the number of TUNEL-positive
cells in the ischemic penumbra. Pretreatment with EA significantly decreased the number of TUNEL-positive cells, while the a7nAChR antagonist
a-BGT attenuated the reduction (n = 5). *P < 0.01 vs. MCAO, #P < 0.01 vs. EA+MCAO.
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gesting that there is a time window following the onset
of stroke in which recovery is possible. Apoptosis is
known to contribute to cell death of ischemic brain tis-
sue, and inhibition of apoptosis reduces ischemic injury
[35]. We found numerous apoptotic neurons in the
ischemic penumbra of controlled ischemic animals,
whereas EA pretreatment significantly reduced the num-
ber of apoptotic neurons, suggesting that EA pretreat-
ment alleviates neuronal apoptosis. Moreover, HMGB1
levels in the penumbral brain tissue and plasma corre-
lated well with the numbers of apoptotic neuronal cells
in the ischemic penumbra, potentially suggesting a role
of HMGB1 inhibition in the alleviation of neuronal
apoptosis by EA. In accordance with our experimental
results, other in vitro studies have shown that HMGB1
release from macrophages was correlated with the
occurrence of apoptosis, and it was suggested that these
processes reflect common mechanisms [36]. However,
other studies have shown that HMGB1 production
occurred downstream of apoptosis in the final common
pathway to organ damage in severe sepsis [37]. Thus,
the crosstalk between HMGB1 and apoptosis needs to
be further explored.
Conclusion
In summary, our results strongly suggest that EA pre-
treatment affords strong protection against transient
Figure 6 Levels of high-mobility group box 1 (HMGB1) in the penumbral cytoplasm and plasma. (A) HMGB1 content in the penumbral
cytoplasm 72 h after reperfusion. (B) HMGB1 concentration in plasma 72 h after reperfusion. Each value represents the mean ± SEM of five
measurements. *P < 0.01 vs. MCAO, #P < 0.01 vs. EA+MCAO. (C) The relationship between the numbers of apoptotic neuronal cells and brain
HMGB1 content (n = 25 pairs, r = 0.8409, P < 0.01). (D) The relationship between the numbers of apoptotic neuronal cells and plasma HMGB1
concentrations (n = 25 pairs, r = 0.7263, P < 0.01).
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through a7nAChR activation in rats. Although further
studies are needed to elucidate the exact signaling cas-
cades between a7nAChR and HMGB1, and to under-
stand the crosstalk between HMGB1 and apoptosis, our
findings may represent a novel mechanism of EA-
induced tolerance to focal cerebral ischemia in rats.
Further, the results also provide strong support for the
possibility of a7nAChR-mediated anti-inflammatory
interventions after stroke.
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Figure 7 Involvement of a7nAChR in OGD-induced HMGB1 release in primary cultured neurons. (A) Effect of PHA-543,613 and a-BGT on
cell viability in normal cultured primary neurons. (B-D) Effects of PHA-543,613 and a-BGT in neurons exposed to OGD on cell viability (B), LDH
release (C) and HMGB1 levels (D). The PHA-543,613 (0-12.5 μM) and a-BGT (10 nM) were incubated with primary cultured neurons for 24 h. PHA-
543,613 was added immediately before the onset of OGD. The a-BGT was pre-incubated with neurons for 30 min before the onset of OGD. The
control cells (0 μM) received vehicle (saline). The cell viability (MTT assay), LDH release and HMGB1 level were tested at 24 h after the exposure
of cell cultures to OGD. *P < 0.05 compared with the 0 μM group exposed to OGD.
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